12 research outputs found
Impacts of biomedical hashtag-based Twitter campaign: #DHPSP utilization for promotion of open innovation in digital health, patient safety, and personalized medicine
The open innovation hub Digital Health and Patient Safety Platform (DHPSP) was recently established with the purpose to invigorate collaborative scientific research and the development of new digital products and personalized solutions aiming to improve human health and patient safety. In this study, we evaluated the effectiveness of a Twitter-based campaign centered on using the hashtag #DHPSP to promote the visibility of the DHPSP initiative. Thus, tweets containing #DHPSP were monitored for five weeks for the period 20.10.2020–24.11.2020 and were analyzed with Symplur Signals (social media analytics tool). In the study period, a total of 11,005 tweets containing #DHPSP were posted by 3020 Twitter users, generating 151,984,378 impressions. Analysis of the healthcare stakeholder-identity of the Twitter users who used #DHPSP revealed that the most of participating user accounts belonged to individuals or doctors, with the top three user locations being the United States (501 users), the United Kingdom (155 users), and India (121 users). Analysis of co-occurring hashtags and the full text of the posted tweets further revealed that the major themes of attention in the #DHPSP Twitter-community were related to the coronavirus disease 2019 (COVID-19), medicine and health, digital health technologies, and science communication in general. Overall, these results indicate that the #DHPSP initiative achieved high visibility and engaged a large body of Twitter users interested in the DHPSP focus area. Moreover, the conducted campaign resulted in an increase of DHPSP member enrollments and website visitors, and new scientific collaborations were formed. Thus, Twitter campaigns centered on a dedicated hashtag prove to be a highly efficient tool for visibility-promotion, which could be successfully utilized by healthcare-related open innovation platforms or initiatives
Serum metabolomics analysis reveals increased lipid catabolism in mildly hyperbilirubinemic Gilbert's syndrome individuals
Background: The protective role of mildly elevated bilirubin against CVD and diabetes mellitus type 2 (DMT2) is associated with a favorable lipid phenotype. As the mechanistic understanding of this protection in humans remains elusive, we aimed to assess the metabolomics profile of mildly hyperbilirubinemic (Gilbert's syndrome; GS) individuals especially targeting lipid catabolism. Methods and results: Using NMR serum metabolomics of 56 GS individuals and 56 age and gender-matched healthy controls, GS individuals demonstrated significantly greater concentrations of acetylcarnitine (+20%, p < 0.001) and the ketone bodies, 3-hydroxybutyric acid (+132%, p < 0.001), acetoacetic acid (+95%, p < 0.001) and acetone (+46%, p < 0.001). Metabolites associated with an increased mitochondrial lipid metabolism such as citrate (+15%, p < 0.001), anaplerotic amino acid intermediates and creatinine were significantly greater and creatine significantly reduced in GS individuals. Stimulators of lipid catabolism including AMPK (+59%, p < 0.001), pPPAR alpha (+24%, p < 0.001) and T3 (+9%, p = 0.009) supported the metabolomics data while concomitantly blood glucose and insulin (-33%, p = 0.002) levels were significantly reduced. We further showed that the increased lipid catabolism partially mediates the favorable lipid phenotype (lower triglycerides) of GS individuals. Increased trimethylamine (+35%, p < 0.001) indicated changes in trimethylamine metabolism, an emerging predictor of metabolic health. Conclusion: We showed an enhanced lipid catabolism in mildly hyperbilirubinemic individuals, novel evidence as to why these individuals are leaner and protected against chronic metabolic diseases emphasizing bilirubin to be a promising future target in obese and dyslipidemia patients. (c) 2021 Published by Elsevier Inc
Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia
Progesterone therapy is a viable treatment for complex atypical hyperplasia (CAH) and endometrial adenocarcinoma, though reliable molecular determinants of response are not available. To explore if analysis of pre-therapy endometrial biopsies could yield biomarkers of response to progesterone, patients with CAH or adenocarcinoma undergoing treatment with progestins were included in this cross-sectional study. Immunohistochemistry for progesterone receptor (PR) was performed. Manual PR expression scores (PRES) were first calculated for biopsies by counting PR-positive nuclei in 12 sensitive vs 9 resistant samples. Significant differences in manual PRES were detected in the stroma (p < 0.01) and total endometrium (p < 0.01) for sensitive vs resistant patients. Manual PRES in the stroma had the highest accuracy in segregating sensitive vs resistant patients (96%). Differences in epithelial PRES were not significant. To validate these findings, a correlation between manual PRES and visual PRES was performed in the 21 patients. An additional 11 patients were analyzed to test if visual PRES would be predictive of response to progesterone. Visual PRES in epithelia and stroma in the 32 specimens was calculated. Significant differences in visual PRES were detected in the stroma for sensitive vs resistant samples (p < 0.01), while differences in epithelial and total endometrium were not significant. Whole genome bisulfite sequencing was performed on DNA isolated using pre-therapy biopsies from 6 sensitive and 6 resistant patients in this cohort. Differentially methylated regions were identified in the stroma and epithelium when evaluating sensitive vs resistant samples. Pathways involved in cell adhesion demonstrated the greatest difference in methylation in these sample
Recommended from our members
Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia.
Progesterone therapy is a viable treatment for complex atypical hyperplasia (CAH) and endometrial adenocarcinoma, though reliable molecular determinants of response are not available. To explore if analysis of pre-therapy endometrial biopsies could yield biomarkers of response to progesterone, patients with CAH or adenocarcinoma undergoing treatment with progestins were included in this cross-sectional study. Immunohistochemistry for progesterone receptor (PR) was performed. Manual PR expression scores (PRES) were first calculated for biopsies by counting PR-positive nuclei in 12 sensitive vs 9 resistant samples. Significant differences in manual PRES were detected in the stroma (p < 0.01) and total endometrium (p < 0.01) for sensitive vs resistant patients. Manual PRES in the stroma had the highest accuracy in segregating sensitive vs resistant patients (96%). Differences in epithelial PRES were not significant. To validate these findings, a correlation between manual PRES and visual PRES was performed in the 21 patients. An additional 11 patients were analyzed to test if visual PRES would be predictive of response to progesterone. Visual PRES in epithelia and stroma in the 32 specimens was calculated. Significant differences in visual PRES were detected in the stroma for sensitive vs resistant samples (p < 0.01), while differences in epithelial and total endometrium were not significant. Whole genome bisulfite sequencing was performed on DNA isolated using pre-therapy biopsies from 6 sensitive and 6 resistant patients in this cohort. Differentially methylated regions were identified in the stroma and epithelium when evaluating sensitive vs resistant samples. Pathways involved in cell adhesion demonstrated the greatest difference in methylation in these samples
Cell-free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes
Although analysis of maternal plasma cell-free content has been employed for screening of genetic abnormalities within a pregnancy, limited attention has been paid to its use for the detection of adverse pregnancy outcomes (APOs) based on placental function. Here we investigated cell-free DNA and RNA content of 102 maternal and 25 cord plasma samples. Employing a novel deconvolution methodology, we found that during the first trimester, placenta-specific DNA increased prior to the subsequent development of gestational diabetes with no change in patients with preeclampsia while decreasing with maternal obesity. Moreover, using cell-free RNA sequencing, APOs revealed 71 differentially expressed genes early in pregnancy. We noticed the upregulation of S100A8, MS4A3, and MMP8 that have been already associated with APOs but also the upregulation of BCL2L15 and the downregulation of ALPL that have never been associated with APOs. We constructed a classifier with a positive predictive ability (AUC) of 0.91 for APOs, 0.86 for preeclampsia alone and 0.64 for GDM. We conclude that placenta-specific cell-free nucleic acids during early gestation provide the possibility of predicting APOs prior to the emergence of characteristic clinical features
A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes
BACKGROUND: Although curcumin's effect on head and neck cancer has been studied
in vitro and in vivo, to the authors' knowledge its efficacy is limited by poor
systemic absorption from oral administration. APG-157 is a botanical drug
containing multiple polyphenols, including curcumin, developed under the US Food
and Drug Administration's Botanical Drug Development, that delivers the active
components to oromucosal tissues near the tumor target.
METHODS: A double-blind, randomized, placebo-controlled, phase 1 clinical trial
was conducted with APG-157 in 13 normal subjects and 12 patients with oral
cancer. Two doses, 100 mg or 200 mg, were delivered transorally every hour for
3 hours. Blood and saliva were collected before and 1 hour, 2 hours, 3 hours, and
24 hours after treatment. Electrocardiograms and blood tests did not demonstrate
any toxicity.
RESULTS: Treatment with APG-157 resulted in circulating concentrations of
curcumin and analogs peaking at 3 hours with reduced IL-1β, IL-6, and IL-8
concentrations in the salivary supernatant fluid of patients with cancer.
Salivary microbial flora analysis showed a reduction in Bacteroidetes species in
cancer subjects. RNA and immunofluorescence analyses of tumor tissues of a
subject demonstrated increased expression of genes associated with
differentiation and T-cell recruitment to the tumor microenvironment.
CONCLUSIONS: The results of the current study suggested that APG-157 could serve
as a therapeutic drug in combination with immunotherapy.
LAY SUMMARY: Curcumin has been shown to suppress tumor cells because of its
antioxidant and anti-inflammatory properties. However, its effectiveness has been
limited by poor absorption when delivered orally. Subjects with oral cancer were
given oral APG-157, a botanical drug containing multiple polyphenols, including
curcumin. Curcumin was found in the blood and in tumor tissues. Inflammatory
markers and Bacteroides species were found to be decreased in the saliva, and
immune T cells were increased in the tumor tissue. APG-157 is absorbed well,
reduces inflammation, and attracts T cells to the tumor, suggesting its potential
use in combination with immunotherapy drugs
“Gilbert’s-like” syndrome as part of a spectrum of persistent unconjugated hyperbilirubinemia in post-chronic hepatitis patients
Circulating cell-free DNA, telomere length and bilirubin in the Vienna Active Ageing Study: exploratory analysis of a randomized, controlled trial
Impacts of biomedical hashtag-based Twitter campaign: #DHPSP utilization for promotion of open innovation in digital health, patient safety, and personalized medicine
none63siThe open innovation hub Digital Health and Patient Safety Platform (DHPSP) was recently established with the purpose to invigorate collaborative scientific research and the development of new digital products and personalized solutions aiming to improve human health and patient safety. In this study, we evaluated the effectiveness of a Twitter-based campaign centered on using the hashtag #DHPSP to promote the visibility of the DHPSP initiative. Thus, tweets containing #DHPSP were monitored for five weeks for the period 20.10.2020–24.11.2020 and were analyzed with Symplur Signals (social media analytics tool). In the study period, a total of 11,005 tweets containing #DHPSP were posted by 3020 Twitter users, generating 151,984,378 impressions. Analysis of the healthcare stakeholder-identity of the Twitter users who used #DHPSP revealed that the most of participating user accounts belonged to individuals or doctors, with the top three user locations being the United States (501 users), the United Kingdom (155 users), and India (121 users). Analysis of co-occurring hashtags and the full text of the posted tweets further revealed that the major themes of attention in the #DHPSP Twitter-community were related to the coronavirus disease 2019 (COVID-19), medicine and health, digital health technologies, and science communication in general. Overall, these results indicate that the #DHPSP initiative achieved high visibility and engaged a large body of Twitter users interested in the DHPSP focus area. Moreover, the conducted campaign resulted in an increase of DHPSP member enrollments and website visitors, and new scientific collaborations were formed. Thus, Twitter campaigns centered on a dedicated hashtag prove to be a highly efficient tool for visibility-promotion, which could be successfully utilized by healthcare-related open innovation platforms or initiatives.noneKletecka-Pulker M.; Mondal H.; Wang D.; Parra R.G.; Maigoro A.Y.; Lee S.; Garg T.; Mulholland E.J.; Devkota H.P.; Konwar B.; Patnaik S.S.; Lordan R.; Nawaz F.A.; Tsagkaris C.; Rayan R.A.; Louka A.M.; De R.; Badhe P.; Schaden E.; Willschke H.; Maleczek M.; Boyina H.K.; Khalid G.M.; Uddin M.S.; Sanusi; Khan J.; Odimegwu J.I.; Yeung A.W.K.; Akram F.; Sai C.S.; Bucher S.; Paswan S.K.; Singla R.K.; Shen B.; Di Lonardo S.; Tosevska A.; Simal-Gandara J.; Zec M.; Gonzalez-Burgos E.; Habijan M.; Battino M.; Giampieri F.; Tikhonov A.; Cianciosi D.; Forbes-Hernandez T.Y.; Quiles J.L.; Mezzetti B.; Babiaka S.B.; Ahmed M.E.O.; Piccard P.; Urquiza M.S.; Depew J.R.; Schultz F.; Sur D.; Pai S.R.; Gaman M.-A.; Cenanovic M.; Tzvetkov N.T.; Tripathi S.K.; Kharat K.R.; Garcia-Sosa A.T.; Sieber S.; Atanasov A.G.Kletecka-Pulker, M.; Mondal, H.; Wang, D.; Parra, R. G.; Maigoro, A. Y.; Lee, S.; Garg, T.; Mulholland, E. J.; Devkota, H. P.; Konwar, B.; Patnaik, S. S.; Lordan, R.; Nawaz, F. A.; Tsagkaris, C.; Rayan, R. A.; Louka, A. M.; De, R.; Badhe, P.; Schaden, E.; Willschke, H.; Maleczek, M.; Boyina, H. K.; Khalid, G. M.; Uddin, M. S.; Sanusi, ; Khan, J.; Odimegwu, J. I.; Yeung, A. W. K.; Akram, F.; Sai, C. S.; Bucher, S.; Paswan, S. K.; Singla, R. K.; Shen, B.; Di Lonardo, S.; Tosevska, A.; Simal-Gandara, J.; Zec, M.; Gonzalez-Burgos, E.; Habijan, M.; Battino, M.; Giampieri, F.; Tikhonov, A.; Cianciosi, D.; Forbes-Hernandez, T. Y.; Quiles, J. L.; Mezzetti, B.; Babiaka, S. B.; Ahmed, M. E. O.; Piccard, P.; Urquiza, M. S.; Depew, J. R.; Schultz, F.; Sur, D.; Pai, S. R.; Gaman, M. -A.; Cenanovic, M.; Tzvetkov, N. T.; Tripathi, S. K.; Kharat, K. R.; Garcia-Sosa, A. T.; Sieber, S.; Atanasov, A. G